The number needed to harm: Is it too optimistic?

Canadian Journal of Cardiology

Volumn 19, Issue 13, 2003, Pages 1490-1492

  Massel, David ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Clinical trials; Epidemiology; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG FATALITY; HUMAN; META ANALYSIS; PHYSICAL DISABILITY; RISK; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; STROKE;

CLINICAL TRIALS; RISK ASSESSMENT; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 0942266399     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequence of treatment. N Engl J Med 1988;318:1728-33.
2. Cook RJ, Sackett DL. The number needed to treat: A clinically useful measure of treatment effect. BMJ 1995;310:452-4.
3. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712-20.
4. Forrow L, Taylor WC, Arnold RM. Absolutely relative: How research results are summarized can affect treatment decisions. Am J Med 1992;92:121-4.
5. Butcher CH, Weinbacher M, Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ 1994;309:761-4.
6. Naylor CD, Chen E, Strauss B. Measured enthusiasm: Does the method of reporting trial results alter perceptions of therapeutic effectiveness. Ann Intern Med 1992;117:916-21.
7. Lacy CR, Barone JA, Suh D-C, et al. Impact of presentation of research results on the likelihood of prescribing medications to patients with left ventricular dysfunction. Am J Cardiol 2001;87:203-7.
8. McGettigan P, Sly K, O'Connell D, Hill S, Henry D. The effects of information framing on the practices of physicians. J Gen Intern Med 1999;14:633-42.
9. Massel D, Cruickshank M. Greater expectations in a cancer trial: Absolute more than relative survival increases, community more than academic clinicians. Cancer Invest 2000;18:798-803.
10. Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence Based Medicine. London: Churchill Livingstone, 1997.
11. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
12. The GUSTO Investigators. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
13. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-1 trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995;92:2811-8.
14. Kahnemann D, Tversky A. Prospect theory: An analysis of decision under risk. Econometrica 1979;47:263-91.
15. Feinstein A. The 'chagrin factor' and qualitative decision analysis. Arch Intern Med 1985;145:1257-9.
16. Kassirer JP. Incorporating patients' preferences into medical decisions. N Engl J Med 1994;330:1895-6. (Edit)
17. O'Meara JJ III, McNutt RA, Evans AT, Moore SW, Downs SM. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 1994;330:1864-9.
18. Heyland DK, Gafni A, Levine MAH. Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective. J Clin Epidemiol 2000;53:888-94.
19. Stanek EJ, Cheng JWM, Peeples PJ, Simko RJ, Spinler SA. Patient preferences for thrombolytic therapy in acute myocardial infarction. Med Decis Making 1997;17:464-71.
20. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science 1981;211:453-8.